Lilly :Mounjaro Shows 2.2% A1C Drop In Phase 3 Trial For Children & Adolescents With Type 2 Diabetes
(RTTNews) - Eli Lilly and Co. (LLY) announced detailed results from SURPASS-PEDS, the first Phase 3 trial evaluating the safety and efficacy of Mounjaro (tirzepatide)—a GIP/GLP-1 dual receptor agonist—in children and adolescents (ages 10 to under 18) with type 2 diabetes inadequa
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
